|  |  |
| --- | --- |
| **Baby’s name** |  |
| **Transferring site** |  |
| **Receiving site** |  |
| **NHS number** |  |
| **Baby’s Study ID** | AZ |

|  |  |
| --- | --- |
| **Status within the trial** | **Initials** |
| **Consent form** | |
| * + - A copy of the consent form is appended to the email alongside this Transfer Cover Sheet |  |
| **Intervention** | |
| * + - The baby has completed AZTEC IMP. **The IMP is not accompanying the infant** |  |
| * + - The baby is being transferred to an AZTEC Recruiting Site. **The IMP is accompanying the infant**   **Pack ID: \_\_\_\_\_\_\_\_\_\_\_\_\_ Next dose: Day\_\_\_\_\_\_\_\_\_\_ of 10** |  |
| * + - The baby is being transferred to an AZTEC Continuing Care Site. **The IMP is not accompanying** the infant |  |
| **Daily log** | |
| * + - The baby **has completed** the 21 day post-randomisation surveillance period- the daily log **is complete** |  |
| * + - The baby **has not completed** the 21 day post-randomisation surveillance period- the daily **log is not complete**. Please complete the daily log **from Day \_\_\_\_\_ onwards** |  |
| **Primary outcome** | |
| * + - The baby is being transferred prior to 36 weeks’ postmenstrual age. The **primary outcome assessment is due on: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ (±5 days)** |  |
| * + - The baby is being transferred after 36 weeks’ postmenstrual age. The Primary outcome assessment is complete |  |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Person preparing the transfer** | |  | | |
| **Contact number** |  | | **Contact email** |  |
| **Name of receiving PI at continuing care site** | | |  | |

|  |  |  |  |
| --- | --- | --- | --- |
| **CTR contact details** | John Lowe, Trial Manager | | |
| **Contact number** | 029 2068 7990 | **Contact email** | AZTEC@Cardiff.ac.uk |